Search

Your search keyword '"Sanchez, James F."' showing total 145 results
Start Over Author "Sanchez, James F." Language english
145 results on '"Sanchez, James F."'

1. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Author

Murtadha, Mariam, Park, Miso, Zhu, Yinghui, Caserta, Enrico, Napolitano, Ottavio, Tandoh, Theophilus, Moloudizargari, Milad, Pozhitkov, Alex, Singer, Mahmoud, Dona, Ada Alice, Vahed, Hawa, Gonzalez, Asaul, Ly, Kevin, Ouyang, Ching, Sanchez, James F., Nigam, Lokesh, Duplan, Amanda, Chowdhury, Arnab, Ghoda, Lucy, Li, Ling, Zhang, Bin, Krishnan, Amrita, Marcucci, Guido, Williams, John C., and Pichiorri, Flavia

Published
2024
Full Text
View/download PDF

2. Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.

Author

Dona, Ada Alice, Tandoh, Theophilus, Nigam, Lokesh, Singer, Mahmoud, Caserta, Enrico, Murtadha, Mariam, Zhu, Yinghui, Moloudizargari, Milad, Sharma, Preeti, Napolitano, Ottavio, Winchester, Janet, Chowdhury, Arnab, Pozhitkov, Alex, Sanchez, James F., Vahed, Hawa, Marcucci, Guido, Coffey, Matt, Nuovo, Gerard, Sborov, Douglas W., and Pichiorri, Flavia

Subjects
MEDICAL sciences, CANCER cells, WESTERN immunoblotting, PROTEASOME inhibitors, MULTIPLE myeloma
Abstract

Background: Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral replication in the cancer cells was not observed. The combination with proteasome inhibitors (PIs) has shown to enhance RV therapeutic activity, but the mechanisms of action have not been fully elucidated. Methods: Electron microscopy, q-RT-PCR, single-cell mass cytometry (CyTOF), flow cytometry, plaque assays, immunohistochemistry, and Western blot analysis were used to assess RV infection of both myeloma and immune cells. Immune fluorescence, flow cytometry, and luciferase reporter assays were used to assess NF-κB pathway activation upon RV treatments. Immune profiling changes, both ex vivo and in MM patients, were analyzed by flow cytometry and CyTOF analysis. T-cell receptor (TCR) sequencing was also conducted both in immune competent MM mice and in patients enrolled in a phase 1b trial per a standard 3 + 3 dose escalation schedule. Results: Here we show ex vivo and in vivo that proteasome inhibitors (PIs) potentiate reovirus replication in circulating classical monocytes, increasing viral delivery to myeloma cells. We found that the anti-viral signals in monocytes primarily rely on NF-κB activation and that this effect is impaired by the addition of PIs. Conversely, the addition of PIs to RV therapy supports immune activation and killing of MM, independently of direct PI sensitivity. To validate the importance of PIs in enhancing oncolytic viral therapy independently of their killing activity on cancer cells, we then conducted a phase 1b trial of the reovirus Pelareorep together with the PI carfilzomib in 13 heavily pretreated PI-resistant MM patients. Objective responses, which were associated with active reovirus replication in MM cells, T cell activation, and monocytic expansion, were noted in 70% of patients. Conclusions: Although characterized as immunosuppressive drugs, PIs improved RV delivery to MM cells but also enhanced anti-MM efficacy through immune-mediated killing of myeloma cells, independently of their PI sensitivity. These results highlight a more generalizable use of PIs as therapeutic companions to support oncolytic-based therapies in cancers. Trial registration: clinicaltrials.gov, NCT 02101944. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

4. Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo

Author

Ghose, Jayeeta, Dona, Ada, Murtadha, Mariam, Gunes, Emine Gulsen, Caserta, Enrico, Yoo, Ji Young, Russell, Luke, Jaime-Ramirez, Alena Cristina, Barwick, Benjamin G., Gupta, Vikas A., Sanchez, James F., Sborov, Douglas W., Rosen, Steven T., Krishnan, Amrita, Boise, Lawrence H., Kaur, Balveen, Hofmeister, Craig C., and Pichiorri, Flavia

Published
2021
Full Text
View/download PDF

5. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

Author

Krishnan, Amrita, Adhikarla, Vikram, Poku, Erasmus K., Palmer, Joycelynne, Chaudhry, Ammar, Biglang-awa, Van Eric, Bowles, Nicole, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Karanes, Chatchada, Simpson, Jennifer, Sanchez, James F., Yamauchi, Dave, Parayno, Maria, Chowdhury, Arnab, Caserta, Enrico, Marcucci, Guido, Rockne, Russell, Wu, Anna M., Wong, Jeffrey, Forman, Stephen J., Colcher, David, Yazaki, Paul, Shively, John, and Pichiorri, Flavia

Published
2020
Full Text
View/download PDF

6. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

Author

Viola, Domenico, Dona, Ada, Caserta, Enrico, Troadec, Estelle, Besi, Francesca, McDonald, Tinisha, Ghoda, Lucy, Gunes, Emine Gulsen, Sanchez, James F., Khalife, Jihane, Martella, Marianna, Karanes, Chatchada, Htut, Myo, Wang, Xiuli, Rosenzweig, Michael, Chowdhury, Arnab, Sborov, Douglas, Miles, Rodney R., Yazaki, Paul J., Ebner, Todd, Hofmeister, Craig C., Forman, Stephen J., Rosen, Steven T., Marcucci, Guido, Shively, John, Keats, Jonathan J., Krishnan, Amrita, and Pichiorri, Flavia

Published
2021
Full Text
View/download PDF

7. Multi-institutional evaluation of MVCT guided patient registration and dosimetric precision in total marrow irradiation: A global health initiative by the international consortium of total marrow irradiation

Author

Zuro, Darren, Vagge, Stefano, Broggi, Sara, Agostinelli, Stefano, Takahashi, Yutaka, Brooks, Jamison, Leszcynska, Paulina, Liu, An, Zucchetti, Claudio, Saldi, Simonetta, Han, Chunhui, Cattaneo, Mauro, Giebel, Sebastian, Mahe, Marc Andre, Sanchez, James F., Alaei, Parham, Anna, Chiara, Dusenbery, Kathryn, Pierini, Antonio, Storme, Guy, Aristei, Cynthia, Wong, Jeffrey Y.C., and Hui, Susanta

Published
2019
Full Text
View/download PDF

9. Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting

Author

Buettner, Ralf, Morales, Corey, Caserta, Enrico, Troadec, Estelle, Gunes, Emine G., Viola, Domenico, Khalife, Jihane, Li, Hongzhi, Keats, Jonathan J., Christofferson, Austin, Wu, Xiwei, Synold, Timothy W., Palmer, Joycelynne, Sanchez, James F., Pozhitkov, Alexander, Vaidehi, Nagarajan, Marcucci, Guido, Krishnan, Amrita, Rosenzweig, Michael A., Pichiorri, Flavia, and Rosen, Steven T.

Published
2019
Full Text
View/download PDF

10. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report

Author

Sahebi, Firoozeh, Garderet, Laurent, Kanate, Abraham S., Eikema, Diderik-Jan, Knelange, Nina Simone, Alvelo, Omar F. Dávila, Koc, Yener, Blaise, Didier, Bashir, Qaiser, Moraleda, José M., Dreger, Peter, Sanchez, James F., Ciurea, Stefan, Schouten, Harry, Shah, Nirav N., Verbeek, Mareike, Rösler, Wolf, Diez-Martin, Jose L., Schoenland, Stefan, D'Souza, Anita, Kröger, Nicolaus, and Hari, Parameswaran

Published
2019
Full Text
View/download PDF

12. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Author

Sahebi, Firoozeh, Iacobelli, Simona, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Reményi, Péter, Russell, Nigel H., Ljungman, Per, Kobbe, Guido, Apperley, Jane, Trneny, Marek, Krejci, Marta, Wiktor-Jedrzejczak, Wieslaw, Sanchez, James F., Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Browne, Paul, Scheid, Christof, Wilson, Keith M.O., Yakoub-Agha, Ibrahim, Muñiz, Soledad González, Schönland, Stefan, Morris, Curly, Garderet, Laurent, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

13. Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission

Author

Stein, Anthony S., Al Malki, Monzr M., Yang, Dongyun, Palmer, Joycelynne M, Tsai, Ni-Chun, Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Artz, Andrew, Dandapani, Savita, Farol, Len, Hui, Susanta, Liu, An, Nakamura, Ryotaro, Pullarkat, Vinod, Radany, Eric, Rosenthal, Joseph, Salhotra, Amandeep, Sanchez, James F, Spielberger, Ricardo, Marcucci, Guido, Forman, Stephen J, and Wong, Jeffrey

Published
2022
Full Text
View/download PDF

17. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia

Author

Stein, Anthony, Palmer, Joycelynne, Tsai, Ni-Chun, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Farol, Len, Karanes, Chatchada, Khaled, Samer, Liu, An, O'Donnell, Margaret, Parker, Pablo, Pawlowska, Anna, Pullarkat, Vinod, Radany, Eric, Rosenthal, Joseph, Sahebi, Firoozeh, Salhotra, Amandeep, Sanchez, James F., Schultheiss, Tim, Spielberger, Ricardo, Thomas, Sandra H., Snyder, David, Nakamura, Ryotaro, Marcucci, Guido, Forman, Stephen J., and Wong, Jeffrey

Published
2017
Full Text
View/download PDF

18. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Sahebi, Firoozeh, Eikema, Dirk-Jan, Koster, Linda, Kroger, Nicolaus, Meijer, Ellen, van Doesum, Jaap A., Rovira, Montserrat, Koc, Yener, Angelucci, Emanuele, Blaise, Didier, Sammassimo, Simona, McDonald, Andrew, Arroyo, Concepcion Herrera, Sanchez, James F., Forcade, Edouard, Castagna, Luca, Stölzel, Friedrich, Sanz, Jaime, Tischer, Johanna, Ciceri, Fabio, Valcarcel, David, Proia, Anna, Hayden, Patrick J., Beksac, Meral, Yakoub-Agha, Ibrahim, and Schönland, Stefan

Published
2021
Full Text
View/download PDF

21. Telomere position effect is regulated by heterochromatin-associated proteins and NkuA in Aspergillus nidulans

Author

Palmer, Jonathan M., Mallaredy, Sandeep, Perry, Dustin W., Sanchez, James F., Theisen, Jeffrey M., Szewczyk, Edyta, Oakley, Berl R., Wang, Clay C.C., Keller, Nancy P., and Mirabito, Peter M.

Subjects
Telomeres -- Properties, Genetic regulation -- Research, Chromatin -- Properties, Aspergillus -- Genetic aspects, Biological sciences
Abstract

Gene-silencing mechanisms are being shown to be associated with an increasing number of fungal developmental processes. Telomere position effect (TPE) is a eukaryotic phenomenon resulting in gene repression in areas immediately adjacent to telomere caps. Here, TPE is shown to regulate expression of transgenes on the left arm of chromosome III and the right arm of chromosome VI in Aspergillus nidulans. Phenotypes found to be associated with transgene repression included reduction in radial growth and the absence of sexual spores; however, these pleiotropic phenotypes were remedied when cultures were grown on media with appropriate supplementation. Simple radial growth and ascosporogenesis assays provided insights into the mechanism of TPE, including a means to determine its extent. These experiments revealed that the KU70 homologue (NkuA) and the heterochromatin-associated proteins HepA, ClrD and HdaA were partially required for transgene silencing. This study indicates that TPE extends at least 30 kb on chromosome III, suggesting that this phenomenon may be important for gene regulation in subtelomeric regions of A. nidulans. DOI 10.1099/mic.0.039255-0

Published
2010

23. Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Author

Caserta, Enrico, Chea, Junie, Minnix, Megan, Poku, Erasmus K., Viola, Domenico, Vonderfecht, Steven, Yazaki, Paul, Crow, Desiree, Khalife, Jihane, Sanchez, James F., Palmer, Joycelynne M., Hui, Susanta, Carlesso, Nadia, Keats, Jonathan, Kim, Young, Buettner, Ralf, Marcucci, Guido, Rosen, Steven, Shively, John, Colcher, David, Krishnan, Amrita, and Pichiorri, Flavia

Published
2018
Full Text
View/download PDF

25. The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment.

Author

Khalife, Jihane, Sanchez, James F., and Pichiorri, Flavia

Subjects
MULTIPLE myeloma, NON-coding RNA, EXTRACELLULAR vesicles, DIAGNOSIS, PROGNOSIS, PLASMA cell diseases
Abstract

Multiple myeloma (MM) is a cancer of terminally differentiated plasma cells (PCs) that develop at multiple sites within the bone marrow (BM). MM is treatable but rarely curable because of the frequent emergence of drug resistance and relapse. Increasing evidence indicates that the BM microenvironment plays a major role in supporting MM-PC survival and resistance to therapy. The BM microenvironment is a complex milieu containing hematopoietic cells, stromal cells, endothelial cells, immune cells, osteoclasts and osteoblasts, all contributing to the pathobiology of MM, including PC proliferation, escape from immune surveillance, angiogenesis and bone disease development. Small extracellular vesicles (EVs) are heterogenous lipid structures released by all cell types and mediate local and distal cellular communication. In MM, EVs are key mediators of the cross-talk between PCs and the surrounding microenvironment because of their ability to deliver bioactive cargo molecules such as lipids, mRNAs, non-coding regulatory RNA and proteins. Hence, MM-EVs highly contribute to establish a tumor-supportive BM niche that impacts MM pathogenesis and disease progression. In this review, we will first highlight the effects of RNA-containing, MM-derived EVs on the several cellular compartments within the BM microenvironment that play a role in the different aspects of MM pathology. We will also touch on the prospective use of MM-EV-associated non-coding RNAs as clinical biomarkers in the context of "liquid biopsy" in light of their importance as a promising tool in MM diagnosis, prognosis and prediction of drug resistance. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: The Role of Histology

Author

Krishnan, Amrita Y., Palmer, Joycelynne, Nademanee, Auayporn P., Chen, Robert, Popplewell, Leslie L., Tsai, Ni-Chun, Sanchez, James F., Simpson, Jennifer, Spielberger, Ricardo, Yamauchi, Dave, and Forman, Stephen J.

Subjects
Adult, Male, Salvage Therapy, Lymphoma, Non-Hodgkin, Histological Techniques, Remission Induction, Cytarabine, Antibodies, Monoclonal, Middle Aged, Antigens, CD20, Carmustine, Survival Analysis, Article, Young Adult, immune system diseases, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Melphalan, Aged, Etoposide
Abstract

Standard-dose 90yttrium-ibritumomab tiuxetan (0.4 mci/kg) (Zevalin) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation (autoHCT) preparative regimen for non-Hodgkin lymphoma. We report the outcomes of a single-center, single-arm phase II trial of Z-BEAM conditioning in high-risk CD20+ non-Hodgkin lymphoma histologic strata: diffuse large B cell (DLBCL), mantle cell (MCL), follicular (FL), and transformed (TF). Robust overall survival and notably low non-relapse mortality rates (0.9% at day +100 for the entire cohort), with few short and long-term toxicities, confirm the safety and tolerability of the regimen. In addition, despite a high proportion of induction failure patients (46%), the promising response and progression-free survival rates seen in DLBCL (3 year PFS: 71% [95% CI: 55–82% ]), support the premise that the Z-BEAM regimen is particularly effective in this histologic subtype. The role of Z-BEAM in other strata is less clear in the context of the emergence of novel agents.

Published
2017

29. Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study.

Author

Rosenzweig, Michael, Palmer, Joycelynne, Tsai, Ni-Chun, Synold, Tim, Wu, Xiwei, Tao, Shu, Hammond, Samantha N., Buettner, Ralf, Duarte, Lupe, Htut, Myo, Karanes, Chatchada, Nathwani, Nitya, Pichiorri, Flavia, Sahebi, Firoozeh, Sanchez, James F., Chowdhury, Arnab, Krishnan, Amrita, Forman, Stephen J., and Rosen, Steven T.

Subjects
MULTIPLE myeloma, LEFLUNOMIDE, ALANINE aminotransferase, RHEUMATOID arthritis, MONOCLONAL gammopathies, PLASMACYTOMA
Abstract

The inexpensive, well-tolerated, immunomodulatory agent leflunomide, used extensively for the treatment of rheumatoid arthritis, has been shown to produce significant activity against multiple myeloma (MM) in pre-clinical studies. We conducted a phase 1 study (clinicaltrials.gov: NCT02509052) of single agent leflunomide in patients with relapsed/refractory MM (≥3 prior therapies). At dose levels 1 and 2 (20 and 40 mg), no dose-limiting toxicities (DLTs) were observed. At dose level 3 (60 mg), one patient experienced elevated alanine aminotransferase; an additional three patients were enrolled at this dose level without further DLTs. Overall, toxicities were infrequent and manageable. Nine out of 11 patients achieved stable disease (SD), two subjects experiencing SD for nearly one year or longer. The tolerable safety profile of leflunomide, combined with a potential disease stabilization, is motivating future studies of leflunomide, in combination with other MM drugs, or as an approach to delay progression of smoldering MM. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

31. Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML)

Author

Stein, Anthony S., Al Malki, Monzr M., Yang, Dongyun, Palmer, Joycelynne, Tsai, Ni-Chun, Aldoss, Ibrahim, Ali, Haris, Aribi, Ahmed, Artz, Andrew S., Farol, Len, Hui, Susanta, Karanes, Chatchada, Khaled, Samer, Liu, An, Marcucci, Guido, Nakamura, Ryotaro, Pullarkat, Vinod A., Radany, Eric, Rosenthal, Joseph, Salhotra, Amandeep, Sanchez, James F, Spielberger, Ricardo, Snyder, David S, Forman, Stephen J., and Wong, Jeffrey

Published
2020
Full Text
View/download PDF

32. Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia.

Author

Aldoss, Ibrahim, Zhang, Jianying, Pillai, Raju, Shouse, Geoffrey, Sanchez, James F., Mei, Matthew, Nakamura, Ryotaro, Stein, Anthony S., Forman, Stephen J., Marcucci, Guido, and Pullarkat, Vinod

Subjects
LEUKEMIA, ACUTE myeloid leukemia
Abstract

We conducted a retrospective analysis of AML patients treated with the combination of VEN/HMA at our institution between June 2016 and April 2019. Furthermore, we also show a promising CR/CRi rate (38%) in patients with r/r I TP53 i m AML, which includes some patients relapsing after prior alloHCT. Most patients in our cohort received decitabine as their HMA, and this preference may have been influenced by results of a study utilising 10-day courses of decitabine in I TP53 i m myeloid neoplasms and yielding a 100% response rate (Welch I et al i , [10]). Although our preliminary results with VEN/HMA appear favourable compared to the dismal outcomes reported in I TP53 i m AML patients when treated with conventional combination chemotherapy (Grossmann I et al i , [5]; Rucker I et al i , [7]), the median LFS was relatively short, and relapses occurred frequently. [Extracted from the article]

Published
2019
Full Text
View/download PDF

33. First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Author

Krishnan, Amrita Y., Adhikarla, Vikram, Chaudhry, Ammar, Palmer, Joycelynne, Poku, Erasmus K, Biglang-awa, Van Eric, Bowles, Nicole, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Karanes, Chatchada, Simpson, Jennifer, Sanchez, James F, Yamauchi, David, Parayno, Maria, Chowdhury, Arnab, Caserta, Enrico, Wu, Anna, Forman, Stephen J, Colcher, David, Yazaki, Paul, Shively, John E., and Pichiorri, Flavia

Published
2019
Full Text
View/download PDF

37. Immune Mediated Mechanisms of Resistance to Daratumumab

Author

Viola, Domenico, Dona, Ada, Gunes, Emine Gulsen, Troadec, Estelle, Wu, Xiwei, Branciamore, Sergio, McDonald, Tinisha, Ghoda, Lucy, Streatfield, Ashish, Sanchez, James F, Karanes, Chatchada, Htut, Myo, Rosenzweig, Michael, Keats, Jonathan J, Rosen, Steven T, Marcucci, Guido, Krishnan, Amrita, and Pichiorri, Flavia

Published
2018
Full Text
View/download PDF

40. Response to Venetoclax and Hypomethylating Agents Among Prognostic Risk Groups and Genetic Subtypes of Acute Myeloid Leukemia

Author

Aldoss, Ibrahim, Yang, Dongyun, Pillai, Raju, Sanchez, James F, Aribi, Ahmed, Ali, Haris, Sandhu, Karamjeet S, Al Malki, Monzr, Mei, Matthew, Salhotra, Amandeep, Khaled, Samer K., Nakamura, Ryotaro, Sun, Weili, O'Donnell, Margaret R, Snyder, David S, Stein, Anthony S., Forman, Stephen J, Marcucci, Guido, and Pullarkat, Vinod A.

Published
2018
Full Text
View/download PDF

44. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Author

Aldoss, Ibrahim, Yang, Dongyun, Pillai, Raju, Sanchez, James F., Mei, Matthew, Aribi, Ahmed, Ali, Haris, Sandhu, Karamjeet, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Sun, Weili, O'Donnell, Margaret, Snyder, David, Nakamura, Ryotaro, Stein, Anthony S., Forman, Stephen J., Marcucci, Guido, and Pullarkat, Vinod

Published
2019
Full Text
View/download PDF

46. A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics

Author

Krishnan, Amrita, Kapoor, Prashant, Palmer, Joycelynne, Tsai, Ni-Chun, Kumar, Shaji, Lonial, Sagar, Htut, Myo, Karanes, Chatchada, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Somlo, George, Duarte, Lupe, Forman, Stephen J., Sanchez, James F, and Berdeja, Jesus G.

Published
2016
Full Text
View/download PDF

50. Rational Domain Swaps Reveal Insights about ChainLength Control by Ketosynthase Domains in Fungal Nonreducing PolyketideSynthases.

Author

Liu, Ting, Sanchez, James F., Chiang, Yi-Ming, Oakley, Berl R., and Wang, Clay C. C.

Subjects
*POLYKETIDE synthases, *SYNTHASES, *FUNGAL genetics research, *ASPERGILLUS, *ACYLTRANSFERASES
Abstract

A facilegenetic methodology in the filamentous fungus Aspergillusnidulansallowed exchange of the starter unit ACP transacylase(SAT) domainin the nonreduced polyketide synthase (NR-PKS) AfoE of the asperfuranonepathway with the SAT domains from 10 other NR-PKSs. The newly createdhybrid with the NR-PKS AN3386 is able to accept a longer starter unitin place of the native substrate to create a novel aromatic polyketide in vivo. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results